Navigation Links
NeoStem Outlines to Shareholders Near-term and Long-term Business Strategies Following Acquisition of Chinese Pharmaceutical Company
Date:11/19/2009

h, development and distribution capabilities, and is on track to become one of the largest antibiotic producers in Eastern China.

The acquisition of Erye provides us a pharmaceutical distribution system in one of the world's fastest growing consumer markets and we anticipate Erye's recent robust sales and earnings growth to continue. Earlier this year, the Chinese government announced that improving the healthcare for its citizens is a major priority and, according to Forbes.com, China's State Council has approved the spending of $124 billion on its healthcare system between 2009 and 2011. Owning a controlling interest in one of the largest antibiotic producers/distributors in China positions us to take advantage of this growth with products we develop in China and products we develop or license in the US for manufacturing and distribution in China. Given our size and distribution capabilities, any significant product acquisition or development could accelerate our revenue growth.

While NeoStem will continue to offer through Erye traditional pharmaceutical products, we will advance our research and development activities in the US and China focused on stem cell-based therapies beyond hematologic malignancies which have been used therapeutically for over 40 years. The Chinese market for adult stem cell therapies is more advanced than in the US and we look forward to the expansion of these revenue opportunities

We believe that our revenues and profitability will reflect our growth from a service company to a fully integrated international biopharmaceutical company and that this will produce a positive response in the investor market.

NeoStem's market capitalization has increased since the closing of the merger by approximately $40 million to a market capitalization of approximately $59 million as of the writing of this letter. Although the merger resulted in a dilution of the management team's equity ownership
'/>"/>

SOURCE NeoStem, Inc.
Copyright©2009 PR Newswire.
All rights reserved

Page: 1 2 3

Related biology technology :

1. NeoStem Announces NY State License for Adult Stem Cell Collection
2. NeoStem to Present at Third Annual Stem Cell Summit in New York City
3. NeoStems Denis Rodgerson, Ph.D. to Lecture on Stem Cells and Regenerative Medicine at University of Nevada Las Vegas Campus
4. NeoStem Featured in WCBS-TV Health Watch Segment on Adult Stem Cells
5. NeoStem to Expand Stem Cell Collection Center Network to Florida
6. NeoStem Announces Private Placement Financing to Advance Marketing Campaign; Financing Includes Investment from New England Cryogenic Center
7. Suzanne Somers To Promote Growing Importance of Storing Your Own Adult Stem Cells Under Alliance With NeoStem, Inc.
8. NeoStem Expands Adult Stem Cell Collection Network, Gains Footprint in Key Los Angeles Market and Initiates Waitlist
9. NeoStem Forges Ahead in Its Plan to Open Adult Stem Cell Collection Centers in Key Locations that Can Serve as Hubs to Service Clients Nationwide
10. Suzanne Somers, Renowned Author, Medical Advocate, and Official Spokesperson for NeoStem, Inc., Inspires the Audience on The Ellen Degeneres Show
11. NeoStem Secures $250,000 in an Above Market Financing and Expands Its Relationship With New England Cryogenic Center, Inc.
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:8/29/2014)... 29, 2014 Local veterinarian, Dr. Keith ... are seeking candidates to participate in an investigational study ... The ultimate goal of this study is to determine ... one or two arthritically affected joints can help reduce ... Candidates for the current investigational study must be older ...
(Date:8/29/2014)... August 29, 2014 Intrinsic Imaging, ... certified, GAMP® 5 compliant imaging core lab, announced ... Phase II clinical trial to assess a new ... this trial, Intrinsic Imaging will provide comprehensive imaging ... protocol and charter development, site qualification, site training ...
(Date:8/28/2014)... MA (PRWEB) August 28, 2014 “This kit ... test to screen from 0 to 150 ppb,” said Mark ... is a significant benefit to plant owners and USDA-GIPSA inspection ... and other commodities. Testing can take place in a matter ... only can the plant test the feed and grain before ...
(Date:8/28/2014)... August 28, 2014 The ability for ... culture that will allow individuals to perform at the ... important for employers looking to compete in this post–recession ... embracing this trend, as the sector increasingly focuses on ... company, which will have real results on the organization's ...
Breaking Biology Technology:Burnt Hills Veterinary Hospital Seeks Candidates for an Investigational Study of Stem Cells for Dogs with Arthritis 2Intrinsic Imaging Awarded Phase II Clinical Trial to Assess New Treatment for Non-Hodgkin’s Lymphoma 2Klein Hersh International Leads Philadelphia Area Life Science Industry in Company Culture 2Klein Hersh International Leads Philadelphia Area Life Science Industry in Company Culture 3
... For a biotech company, raising money is a saga that never ... do two things: execute on the timely achievement of key milestones ... of your next financing and where and who the money will ... in for a single round whereas most VCs usually commit for ...
...
... predicts the Alzheimer's disease drug market in ... by 15 percent annually for the next five ... entitled "Global Markets for Alzheimer's Disease Medications 2005," ... in an Alzheimer's drug market that generated more ...
Cached Biology Technology:Financing of biotech companies so far in 2005: A Midwest odyssey 2Financing of biotech companies so far in 2005: A Midwest odyssey 3Financing of biotech companies so far in 2005: A Midwest odyssey 4Financing of biotech companies so far in 2005: A Midwest odyssey 5Alzheimer's drug market to hit $5.5 billion by 2009, study says 2
(Date:8/31/2014)... One of the greatest challenges in modern medicine is ... but with minimal toxicity and side-effects to the patient. ... of the drug molecule. Ideally, the drug should have ... target, so that it binds it with high specificity. ... developed a synthetic amino acid that can impact the ...
(Date:8/31/2014)... Climate Change , suggests that if current trends continue ... global targets for total greenhouse gas (GHG) emissions in 2050. ... carefully about the food we choose and its environmental impact. ... one of a number of actions that need to be ... enough food for all. , As populations rise and ...
(Date:8/29/2014)... Researchers at UC Davis have made some surprising ... infection. Studying simian immunodeficiency virus (SIV), the team ... Paneth cells are early responders to viral invasion ... producing a cytokine called interleukin-1 beta (IL-1β). ... IL-1β causes breakdown of the gut epithelium that ...
Breaking Biology News(10 mins):A new synthetic amino acid for an emerging class of drugs 2A new synthetic amino acid for an emerging class of drugs 3Changing global diets is vital to reducing climate change 2Changing global diets is vital to reducing climate change 3Changing global diets is vital to reducing climate change 4The early cost of HIV 2
... at Boulder team working at 16,400 feet in the ... retreating glacier ice can swiftly establish a thriving community ... alpine plants. The discovery is the first to ... one of the most extreme environments on Earth and ...
... choice all too frequently has come down to living ... indoor allergens. Today, The Clorox Company extends its ... Anti-Allergen Fabric Spray, a new product to help manage ... Clorox® Anywhere® Anti-Allergen Fabric Spray denatures dust mite ...
... Humans aren,t the only ones who like fatty foods - ... the Bearded Vulture Study and Protection Group in El Pont ... discard less energy-dense bones and choose only the bones containing ... to its young. His findings will be published this week ...
Cached Biology News:As Andean glacier retreats, tiny life forms swiftly move in, CU-Boulder study shows 2As Andean glacier retreats, tiny life forms swiftly move in, CU-Boulder study shows 3The Clorox Company's new indoor allergen product reduces common indoor allergens up to 90 percent 2Scavenger birds chew the fat 2
Chicken polyclonal to YebU ( Abpromise for all tested applications). Antigen: Synthetic peptide, corresponding to amino acids 196-244 of E. coli YebU....
Mouse monoclonal [6911] to E. coli K99 pilus ( Abpromise for all tested applications)....
... Antibody to CRF The ... ovine CRF sequence that it ... fibres are found in the ... brain in colchicine treated 4% ...
... siSolutions siRNA Custom Synthesis ... effective duplex RNA to knockdown ... 21-mers (19 RNA base pairs ... recently-published 27-mers, or other lengths ...
Biology Products: